Abstract

Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).

Keywords

NeprilysinAcute decompensated heart failureHeart failureCardiologyInternal medicineMedicineChemistryEnzyme

Affiliated Institutions

Related Publications

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)

John J.V. McMurray , Milton Packer , Akshay S. Desai +8 more

Aims Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the renin–angiotensin–aldosterone sys...

2013 European Journal of Heart Failure 439 citations

Publication Info

Year
2018
Type
article
Volume
380
Issue
6
Pages
539-548
Citations
1185
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1185
OpenAlex

Cite This

Eric J. Velazquez, David A. Morrow, Adam D. DeVore et al. (2018). Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. New England Journal of Medicine , 380 (6) , 539-548. https://doi.org/10.1056/nejmoa1812851

Identifiers

DOI
10.1056/nejmoa1812851